Urachal cancer is rare and has a prevalence of approximately 0.2%.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases.Cancer. 2007; 110: 2434-2440
- The clinical epidemiology of urachal carcinoma: results of a large, population-based study.J Urol. 2012; 188: 1102-1107
- A case of metastatic urachal adenocarcinoma treated with several different chemotherapeutic regimens.Can Urol Assoc J. 2012; 6: E27-E31
- Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center Experience.J Urol. 2003; 169: 1295-1298
National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0. NIH publication #09–7473. NCI, NIH, DHHS. 2009 May 29. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
- Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C.Urology. 1985; 26: 252-255
- Treatment of metastatic urachal carcinoma in an elderly woman.Nat Clin Pract Oncol. 2008; 5: 55-58
- Combined modalities treatment of pulmonary metastasis from an urachal adenocarcinoma.Rare Tumors. 2013; 5: e32
- Successful treatment of metastatic adenocarcinoma of the urachus: report of 2 cases with more than 10-year survival.Urology. 2001; 58: 462
- Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide, and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus.Int J Urol. 2008; 15: 851-853
- Complete response to M-FAP chemotherapy for multiple lung metastases after segmental resection of urachal carcinoma: a case report.Hinyokika Kiyo. 2010; 56: 107-110
- Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.Urology. 2007; 69: 255-259
- A case of urachal carcinoma treated with S-1/CDDP combination chemotherapy.Hinyokika Kiyo. 2010; 56: 447-451
- Complete response of a recurrent advanced urachal carcinoma treated by S-1/cisplatin combination chemotherapy.Int J Urol. 2006; 13: 1123-1125
- Irinotecan as a new agent for urachal cancer.Urol Int. 2006; 76: 281-282
- Response to targeted therapy in urachal adenocarcinoma.Rare Tumors. 2014; 6: 5529
- High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations.Hum Pathol. 2014; 45: 327-330
- Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.Genes Chromosomes Cancer. 2011; 50: 307-312
- Microsatellite instability in colorectal cancer.Gastroenterology. 2010; 138: 2073-2087.e3
- Roles of EGFR and KRAS mutations in the treatment of patients with non–small-cell lung cancer.Pharm Ther. 2011; 36: 263-279
- KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.PLoS Med. 2005; 2: e17
- The activating mutation R201C in GNAS promotes intestinal tumourigenesis in ApcMin/+ mice via activation of Wnt and ERK1/2 MAPK pathways.Oncogene. 2010; 29: 4567-4575
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.Lancet Oncol. 2013; 14: 38-47
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer. 2009; 45: 228-247
- Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.Blood. 2006; 108: 1339-1345
- AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.Blood. 2005; 106: 265-273
- Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.Blood. 2002; 100: 59-66
- Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.Blood. 2002; 100: 4372-4380
- A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.Br J Haematol. 2015; 169: 694-700
- Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.Blood. 2012; 119: 5133-5143
- Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.Cancer Res. 2008; 68: 5524-5528
- MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.Genes Chromosomes Cancer. 2015; 54: 361-368
- Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K- mutated melanoma.Clin Cancer Res. 2013; 19: 2257-2264
- MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking.Clin Cancer Res. 2015; 21: 1935-1943
- Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.Nat Genet. 2012; 44: 133-139
- MAP kinase genes and colon and rectal cancer.Carcinogenesis. 2012; 33: 2398-2408
- Improved survival with MEK inhibition in BRAF-mutated melanoma.N Engl J Med. 2012; 367: 107-114
- Improved overall survival in melanoma with combined dabrafenib and trametinib.N Engl J Med. 2015; 372: 30-39
- Changes of KRAS exon 2 codon 12/13 mutation status in recurrent colorectal cancer.Pathol Oncol Res. 2015; 21: 399-404
- Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.J Clin Oncol. 2012; 30: 3077-3083
- Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer.JAMA Oncol. 2015; 1: 582-591
- Mechanisms and insights into drug resistance in cancer.Front Pharmacol. 2013; 4: 28
- Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.N Engl J Med. 2012; 366: 883-892
Article info
Publication history
Published online: March 24, 2016
Accepted:
March 19,
2016
Received:
March 3,
2016
Identification
Copyright
© 2016 Elsevier Inc. All rights reserved.
